BofA Securities Downgrades 10X Genomics (TXG) to Underperform
Tweet
Share
E-mailGet Alerts TXG Hot Sheet
Price: $46.14 +1.70%
Rating Summary:
8 Buy, 1 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 15 | New: 17
Rating Summary:
8 Buy, 1 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 15 | New: 17
Join SI Premium – FREE
BofA Securities analyst Derik de Bruin downgraded 10X Genomics (NASDAQ: TXG) from Neutral to Underperform with a price target of $35.00 (from $80.00).
For an analyst ratings summary and ratings history on 10X Genomics click here. For more ratings news on 10X Genomics click here.
Shares of 10X Genomics closed at $43.29 yesterday.
You May Also Be Interested In
- JPMorgan Downgrades Lynas Rare Earths Ltd (LYC:AU) (LYSDY) to Underweight
- Atlantic Equities Downgrades Bank of America (BAC) to Neutral
- Hyundai Glovis Co Ltd (086280:KS) PT Lowered to KRW260,000 at Credit Suisse
Create E-mail Alert Related Categories
Analyst PT Change, Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
